SCHEDULE: FMR LLC Reports 1.4% Stake in Crinetics Pharmaceuticals

FMR LLC and Abigail P. Johnson have updated their Schedule 13G filing, reporting a combined beneficial ownership of 1.4% in Crinetics Pharmaceuticals Inc. common stock as of July 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, indicating their beneficial ownership of Crinetics Pharmaceuticals Inc. common stock.
• As of July 31, 2026, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 1,439,890.88 shares.
• This ownership represents 1.4% of the class of securities.
• FMR LLC holds sole voting power for 1,438,730 shares and sole dispositive power for 1,439,890.88 shares.
• Abigail P. Johnson has sole dispositive power for 1,439,890.88 shares, with no shared voting or dispositive power reported.
• The filing confirms that no single other person's interest in the common stock exceeds five percent of the total outstanding shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an update on beneficial ownership rather than a significant operational or financial disclosure.

Positives

• FMR LLC and Abigail P. Johnson maintain a significant, though passive, investment in Crinetics Pharmaceuticals.
• The filing indicates a stable ownership structure with no indication of activist intent.
• The reporting entities are established financial institutions, suggesting a potentially stable shareholder base.

Negatives

• The filing does not provide any new operational or financial performance data for Crinetics Pharmaceuticals.
• The ownership stake of 1.4% is relatively small and may not confer significant influence on company strategy.

Risks

• Market volatility could impact the value of the reported shares.
• Changes in investment strategy by FMR LLC or Abigail P. Johnson could lead to a reduction or sale of their stake.

Future Outlook

This filing is an update on beneficial ownership and does not contain forward-looking statements or guidance regarding Crinetics Pharmaceuticals Inc.'s future performance.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. This filing indicates FMR LLC and Abigail P. Johnson's continued passive investment in the biotechnology sector, specifically within Crinetics Pharmaceuticals.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant institutional investor's holdings, which can be a factor in market perception.
• Management of Crinetics Pharmaceuticals: The filing confirms a passive investment, suggesting no immediate pressure for strategic changes from this shareholder group.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to report any changes in their beneficial ownership of Crinetics Pharmaceuticals Inc. common stock as required by SEC regulations.

Key Dates

Keywords

Crinetics Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Investment Management, Shareholder Update